It's a bit risky without seeing the P&L. But they did indicate the cumulative loss so far is around $5.5m.
This company is in similar market as Isentia. Given the strong performance of Isentia to date, it could be a good comparison.
I'm thinking on putting a decent amount in this one. But since I'll be applying through the General Public offer, most likely I'll get scaled back heaps.
